ImmunityBio (IBRX) remains under heavy scrutiny from short sellers, with current data indicating a short interest of 30.5% of the float. The stock has been flagged for sustained settlement-level short pressure, having cleared the 50% short-volume ratio bar for at least five consecutive trading days. With a borrow fee of 0.6% and a days-to-cover ratio of 7.7, the stock remains a focal point for traders monitoring Reg SHO threshold list activity. These figures, derived from consolidated NMS short-volume files, highlight a persistent bearish sentiment that has kept the stock on the radar for potential squeeze setups.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.